Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases

Abstract

Background: Buntanetap (formerly Posiphen) is an orally bioavailable small molecule that improves cognitive function in patients with early Alzheimer’s (AD) and Parkinson’s (PD) diseases. Buntanetap is lipophilic and has high blood‐brain barrier penetrability and brain uptake (10:1 brain:plasma ratio).

The paper